{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:53:05Z","timestamp":1782377585110,"version":"3.54.5"},"reference-count":36,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>While minimalist kinetic models effectively capture the acute inverse coupling between Hepatitis B (HBV) and Hepatitis Delta (HDV), they often fail to account for the asymptotic stability and long-term viral plateaus observed during clinical therapy. In this work, we present an expanded compartmental framework integrating the non-linear dynamics of susceptible (S) and infected (I) hepatocyte populations, explicitly incorporating the satellite nature of HDV. Using the next-generation matrix method and Lyapunov stability theory, we analytically derive R0 and prove the global attractivity of the endemic equilibrium. We demonstrate that \u201cTarget Cell Limitation\u201d serves as the fundamental homeostatic governor. A transcritical bifurcation at threshold drug efficacy \u03b5 \u2248 0.9 marks the mathematical boundary between chronic persistence and viral extinction.<\/jats:p>","DOI":"10.3390\/v18070698","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:14:12Z","timestamp":1782375252000},"page":"698","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Topological Stability and Transcritical Bifurcations in a Target-Cell-Limited Model of HBV-HDV Viral Interference"],"prefix":"10.3390","volume":"18","author":[{"given":"Menachem","family":"Lachiany","sequence":"first","affiliation":[{"name":"Department of Computer Science, Western Galilee College, Acre 2412101, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0168-8278(23)00451-8","article-title":"Week 48 results of the phase 3 D-LIVR study","volume":"78","author":"Etzion","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection","volume":"221","author":"Miao","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Zakh, R., Churkin, A., Bietsch, W., Lachiany, M., Cotler, S.J., Ploss, A., Dahari, H., and Barash, D. (2021). A Mathematical Model for Early HBV and -HDV Kinetics during Anti-HDV Treatment. Mathematics, 9.","DOI":"10.3390\/math9243323"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","article-title":"Hepatitis delta virus","volume":"378","author":"Hughes","year":"2011","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Taylor, J.M. (2020). Infection by Hepatitis Delta Virus. Viruses, 12.","DOI":"10.3390\/v12060648"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"a021576","DOI":"10.1101\/cshperspect.a021576","article-title":"Hepatitis D Virus: Introduction and Epidemiology","volume":"5","author":"Rizzetto","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1001\/jama.2023.23242","article-title":"Hepatitis D: A Review","volume":"330","author":"Negro","year":"2023","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D Virus in 2021: Virology, Immunology and New Treatment Approaches for a Difficult-to-Treat Disease","volume":"70","author":"Urban","year":"2021","journal-title":"Gut"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: Regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"ref_11","unstructured":"Eiger BioPharmaceuticals (2023). Study of the Efficacy and Safety of Lonafarnib\/Ritonavir With and Without Pegylated Interferon-Alfa-2a (D-LIVR); ClinicalTrials.gov Identifier: NCT03719313, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03719313 (accessed on 20 April 2026)."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","article-title":"Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: A proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial","volume":"15","author":"Koh","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa2314134","article-title":"Bulevirtide Combined With Pegylated Interferon for Chronic Hepatitis D","volume":"391","author":"Asselah","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jhep.2024.05.001","article-title":"Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial","volume":"81","author":"Wedemeyer","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2018.12.022","article-title":"Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy","volume":"70","author":"Yurdaydin","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): A multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/hep.27357","article-title":"Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling","volume":"60","author":"Guedj","year":"2014","journal-title":"Hepatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jtbi.2016.03.018","article-title":"Dynamics of in vivo hepatitis D virus infection","volume":"398","author":"Goyal","year":"2016","journal-title":"J. Theor. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3851\/IMP2728","article-title":"Treatment of chronic hepatitis D patients with pegylated interferon: A real-world experience","volume":"19","author":"Abbas","year":"2014","journal-title":"Antivir. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrgastro.2016.126","article-title":"Hepatitis delta virus: Insights into a peculiar pathogen and novel treatment options","volume":"13","author":"Lempp","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Mhlanga, A., Zakh, R., Churkin, A., Reinharz, V., Glenn, J.S., Etzion, O., Cotler, S.J., Yurdaydin, C., Barash, D., and Dahari, H. (2022). Modeling the Interplay between HDV and HBV in Chronic HDV\/HBV Patients. Mathematics, 10.","DOI":"10.3390\/math10203917"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2021.12.030","article-title":"Mathematical modeling suggests that entry-inhibitor bulevirtide may interfere with hepatitis D virus clearance from circulation","volume":"76","author":"Shekhtman","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrgastro.2015.97","article-title":"Modelling hepatitis C therapy\u2014predicting effects of treatment","volume":"12","author":"Perelson","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"de Sousa, B.C., and Cunha, C. (2010). Development of Mathematical Models for the Analysis of Hepatitis Delta Virus Viral Dynamics. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012512"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.22586","article-title":"Modeling complex decay profiles of hepatitis B virus during antiviral therapy","volume":"49","author":"Dahari","year":"2009","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11538-024-01284-2","article-title":"Mathematical models of early hepatitis B virus dynamics in humanized mice","volume":"86","author":"Ciupe","year":"2024","journal-title":"Bull. Math. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Goyal, A., Ribeiro, R.M., and Perelson, A.S. (2017). The Role of Infected Cell Proliferation in the Clearance of Acute HBV Infection in Humans. Viruses, 9.","DOI":"10.3390\/v9110350"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41598-020-80594-6","article-title":"Understanding the Antiviral Effects of RNAi-Based Therapy in HBeAg-Positive Chronic Hepatitis B Infection","volume":"11","author":"Kadelka","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Goyal, A., and Murray, J.M. (2014). The Impact of Vaccination and Antiviral Therapy on Hepatitis B and Hepatitis D Epidemiology. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0110143"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jtbi.2007.03.006","article-title":"Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy","volume":"247","author":"Dahari","year":"2007","journal-title":"J. Theor. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1137\/080714579","article-title":"Analysis of Hepatitis C Virus Infection Models with Hepatocyte Homeostasis","volume":"69","author":"Reluga","year":"2009","journal-title":"SIAM J. Appl. Math."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1097\/HEP.0000000000000431","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference","volume":"78","author":"Ghany","year":"2023","journal-title":"Hepatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100280","DOI":"10.1016\/j.jhepr.2021.100280","article-title":"Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B","volume":"3","author":"Buti","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"a021568","DOI":"10.1101\/cshperspect.a021568","article-title":"Hepatitis D Virus Replication","volume":"5","author":"Taylor","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/7\/698\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:45:30Z","timestamp":1782377130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/7\/698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["v18070698"],"URL":"https:\/\/doi.org\/10.3390\/v18070698","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]}}}